Roche Holding AG (DE:RHOA)
FRANKFURT:RHOA
Want to see DE:RHOA full AI Analyst Report?
RHOA Stock Chart & Stats
€342.35
€0.00(0.00%)
At close: 4:00 PM EST
€342.35
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€244.35 - €411.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)397.00
Market Cap
€281.16B
Enterprise Value€282.37B
Total Cash (Recent Filing)€15.48B
Total Debt (Recent Filing)€31.64B
Price to Earnings (P/E)11.9
Beta0.26
Next Earnings
Jul 23, 2026EPS Estimate
11.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.12
Shares Outstanding702,562,700
10 Day Avg. Volume250
30 Day Avg. Volume397
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€380.39Price Target Upside11.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)21.9
Revenue Forecast (FY)€68.07B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthRoche’s sustained high free cash flow (CHF14.1bn in 2025) and historically strong operating cash generation provide durable funding for R&D, capital expenditure and the USD50bn U.S. commitment. High FCF-to-income ratios indicate quality earnings and long‑term capacity to support dividends and strategic investments.
Robust Pharma Pipeline & ExecutionA deep, advancing R&D pipeline (10 NMEs into Phase III and numerous positive readouts/approvals) plus Pharma sales growth supports medium‑term revenue replacement for maturing drugs. Diversified therapeutic franchises and steady clinical progress underpin sustainable organic growth and defend margins over time.
Diagnostics Recurring Revenue & InnovationDiagnostics combines instrument sales with high‑margin recurring consumables and expanding assay menus (new sequencing and mass spec launches). Installed base-led repeat revenue and continuous product innovation create annuity-like cash flows and margin resilience, supporting long-term profitability despite regional shocks.
Bears Say
China Diagnostics Pricing ShockChina healthcare pricing reforms produced a sizable, structural hit to Diagnostics revenues (CHF579m). Prolonged pricing pressure or slower recovery could permanently depress recurring consumables volumes and margins in a major market, challenging near‑term top‑line resilience and requiring offset from other regions or new products.
Loss Of Exclusivity (LOE) RiskExpected LOE-driven revenue erosion (about CHF1bn in 2026 within a recurring CHF1–1.5bn range) represents a durable headwind to sales and cash flow for established franchises. Offsetting this requires timely launches and uptake of pipeline assets; failure to fully replace lost volumes strains growth and margin trajectories.
Working Capital & Cash Conversion FrictionA notable decline in operating free cash flow and a CHF2.2bn working capital drag indicate cash conversion inefficiencies. Persistent inventory/AR build or seasonal timing can constrain funding for M&A, dividends, or capex and weakens leverage improvement, making financial flexibility more sensitive to operational execution.
Roche Holding AG News
RHOA FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was €244.35 and its highest was €411.60 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is €281.16B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 88 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported €9.115 earnings per share for the quarter, missing the consensus estimate of €9.268 by -€0.152.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 11.6.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of €9.115 in its last earnings report, missing expectations of €9.268. Following the earnings report the stock price went up 3.63%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in DE:RHOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHOA Company Deck
RHOA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution: group sales +7% (Pharma +9%), core operating profit +13% and meaningful pipeline momentum with multiple positive Phase III readouts, approvals, a record 10 NMEs entering Phase III and launches (AXELIOS sequencing, mass spec, dengue test). Roche also secured a major U.S. government agreement and committed large U.S. investments. Material headwinds were acknowledged — notably Diagnostics headwinds from China pricing reforms (CHF 579m impact), FX and cash-flow/working capital pressures, higher taxes reducing EPS momentum, LOE effects (~CHF 700m) and safety/regulatory scrutiny (fenebrutinib liver signal). Management provided 2026 guidance (mid-single-digit sales growth, high single-digit Core EPS growth) and expects Diagnostics headwinds to diminish in 2026 and largely disappear by 2027. Overall, the positives from sales, margin expansion, prolific pipeline and strategic investments substantially outweighed the operational and market challenges discussed.View all DE:RHOA earnings summariesRHOA Stock 12 Month Forecast
Average Price Target
€380.39
▲(11.11% Upside)
Options Prices
Currently, No data available
---